Drug intelligence / Profile preview

PMN330

Development stage: Preclinical
Lead developer: ProMIS Neurosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

PMN330 is a monoclonal antibody (mAb) developed by ProMIS Neurosciences for the treatment of Alzheimer's disease. It is specifically designed to target toxic amyloid beta oligomers (AβO), which are considered a primary driver of neurotoxicity in Alzheimer's pathology. Unlike some other amyloid-targeting therapies that bind to monomers or plaques, PMN330 selectively targets the soluble oligomeric form. The drug was identified as a lead development candidate based on its selective target product profile in both in vitro and in vivo tests. Originally developed as a murine antibody, it requires humanization for clinical therapeutic use.

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on PMN330.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMN330.

Explore the full profile